Synopsis: Pharmaceutical company sees strong FY27 growth driven by India business, branded expansion, margin gains, improved efficiency, and early semaglutide traction.
The article outlines this company’s FY27 outlook, which develops and markets branded generics, specialty medicines, and over-the-counter (OTC) drugs, focusing primarily on Dermatology, Respiratory, and Oncology.
With a market capitalization of Rs 61,101 crore, Glenmark Pharmaceuticals Ltd’s shares closed at Rs 2,166 per share, down by 0.71 percent. The share of the company gave a return of 37 percent over the last year.
Management Guidance
Anurag Mantri, Executive Director and Global CFO of Glenmark Pharmaceuticals, guided strong revenue growth and steady margin expansion for FY27, driven by India business growth and a stronger branded portfolio. He also highlighted improving working capital efficiency and encouraging early traction in semaglutide.
FY27 Revenue and Margin Guidance: The company remains confident of achieving revenue of around Rs 17,000-18,000 crore in FY27, along with an operating margin of 21 percent to 22 percent. This outlook reflects expectations of steady demand growth and continued operational efficiency improvements.
India Business Growth Outlook: The India business is expected to grow at around 15 percent in FY27, supported by strong traction across key therapeutic segments. Sustained domestic demand is likely to remain a key driver of overall revenue expansion in the coming period.
Branded Portfolio and Global Expansion: The branded segment continues to remain strong and is expected to stay a core growth driver. Management has guided that branded sales will increase to around 70 percent by 2030, compared to 60 percent currently. In addition, products like Ryaltris have already been launched in markets such as China, supporting the international growth strategy.
Working Capital and New Growth Drivers: Net working capital days are guided at around 115-120 days and have already come in below the guided range, indicating improved balance sheet efficiency. Meanwhile, semaglutide is emerging as a key opportunity, with initial market response described as encouraging.
Key developments in FY26
IGI–AbbVie Landmark Deal: IGI signed a major licensing deal with AbbVie for ISB 2001 developed on its BEAT® platform for oncology and autoimmune diseases. The deal includes USD 700 million upfront, total value up to USD 1.925 billion, and tiered double-digit royalties, with Glenmark leading commercialization in emerging markets.
Oncology Expansion and India Performance: Glenmark strengthened its oncology portfolio through in-licensing of Trastuzumab Rezetecan and Aumolertinib from leading Chinese pharma companies. India business outperformed IPM growth by 1.5 times and ranked second among top 15 firms in FY26. Multiple differentiated launches further reinforced its presence across oncology, respiratory, and diabetes segments.
Global Growth and Manufacturing Update: RYALTRIS continued strong global growth with over 50 percent rise in secondary sales and expansion into China, Thailand, and the US. Dermatology presence expanded in Europe with WINLEVI approval and UK launch. US respiratory portfolio strengthened with key approvals, while Monroe facility restart supports injectable and institutional growth.
Glenmark Pharmaceuticals Ltd. is a research-led global pharmaceutical company headquartered in Mumbai, India. Founded in 1977, it develops and markets branded generics, specialty medicines, and over-the-counter (OTC) drugs, focusing primarily on Dermatology, Respiratory, and Oncology.
Financial Highlight: The revenue from operations grew by 16 percent to Rs 3,771 crore in Q4 FY26 from Rs 3,256 crore in Q4 FY25, and EBIDT grew by 36 percent to Rs 763 crore in Q4 FY26 from Rs 561 crore in Q4 FY25. This was accompanied by an exponential net profit growth of 52 percent to Rs 301 crore in Q4 FY26 from Rs 4.38 crore in Q4 FY25, resulting in an EPS growth of 6,575 percent to Rs 10.68 per share in Q4 FY26 from Rs 0.16 per share in Q4 FY25.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
